Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

BACKGROUND: Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most likely to respond to immune checkpoint inhibitors. TMB is optimally cal...

Descripción completa

Detalles Bibliográficos
Autores principales: Merino, Diana M, McShane, Lisa M, Fabrizio, David, Funari, Vincent, Chen, Shu-Jen, White, James R, Wenz, Paul, Baden, Jonathan, Barrett, J Carl, Chaudhary, Ruchi, Chen, Li, Chen, Wangjuh (Sting), Cheng, Jen-Hao, Cyanam, Dinesh, Dickey, Jennifer S, Gupta, Vikas, Hellmann, Matthew, Helman, Elena, Li, Yali, Maas, Joerg, Papin, Arnaud, Patidar, Rajesh, Quinn, Katie J, Rizvi, Naiyer, Tae, Hongseok, Ward, Christine, Xie, Mingchao, Zehir, Ahmet, Zhao, Chen, Dietel, Manfred, Stenzinger, Albrecht, Stewart, Mark, Allen, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174078/
https://www.ncbi.nlm.nih.gov/pubmed/32217756
http://dx.doi.org/10.1136/jitc-2019-000147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174078/
https://www.ncbi.nlm.nih.gov/pubmed/32217756
http://dx.doi.org/10.1136/jitc-2019-000147

Ejemplares similares